Compare Ecolab Inc. (ECL) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ecolab Inc. vs Vertex Pharmaceuticals Incorporated — how do they compare? Ecolab Inc. trades at $281.36 (market cap $77.96B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B). The key difference: Vertex Pharmaceuticals Incorporated is the larger of the two by market cap, and Ecolab Inc. pays a 1.05% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ecolab Inc. for 90 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| ECL | VRTX | |
|---|---|---|
Market Cap | $77.96B | $128.16B |
Volume | 1,145,536 | 806,603 |
Sector | Basic Materials | Health |
52-Week High | $308.35 | $557.96 |
52-Week Low | $245.73 | $407.37 |
Typical Hold Time | 90 Days | 120 Days |
Enterprise Value | $86.74B | $122.29B |
Dividend Yield | 1.05% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ecolab (ECL) trades at $281.69, up 0.31% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $326.38. The company reported revenue of $16.08B in 2025 with a net income margin of 12.57%, and recent earnings have mostly met or exceeded expectations. Strong institutional buying and insider purchases, alongside positive news coverage highlighting its dividend growth and essential business model, support a constructive outlook.
The stock presents a favorable risk-reward profile given its steady revenue growth, high profitability, and analyst optimism, though elevated valuation ratios and increased debt from the CoolIT acquisition pose risks. The upcoming Q3 2026 earnings report on October 27, 2026, will be a key catalyst for near-term price direction.
Vertex Pharmaceuticals (VRTX) trades at $503.25, showing modest daily gains of 0.16%. The stock faces bearish technical signals with mixed earnings performance, missing Q4 2025 and Q2 2026 EPS estimates but beating Q1 2026. Strong fundamentals include 86% gross margins and 35% net income margins, with revenue projected to grow from $12B to $12.6B in 2026. Recent positive Phase II data for kidney disease drug inaxaplin highlights pipeline progress.
Outlook remains positive with 84% analyst buy ratings and $573 consensus target offering 14% upside. Key risks include reliance on cystic fibrosis franchise and competitive pressures. Earnings consistency and pipeline execution are critical for sustained growth amid current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Ecolab Inc.
Ecolab produces and markets cleaning and sanitation products for the hospitality, healthcare, and industrial markets. The firm is the global market share leader in this category with a wide array of products and services, including dish and laundry washing systems, pest control, and infection control products. The company has a strong hold on the U.S. market and is looking to increase its profitability abroad. Additionally, Ecolab serves customers in water, manufacturing, and life sciences end markets, selling customized solutions.
Read more on ECL →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
